Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Director highlights Calyrex low-cost insulin, tribal consultation and $50 billion rural health application
Summary
Director Lansberg told the board California will launch a state-backed low-cost biosimilar insulin (Calyrex) on Jan. 1, 2026, previewed California's $50 billion federal rural-health application and summarized recent tribal consultation and legislative developments.
Director Lansberg opened the Oct. 17 meeting by previewing the office's major initiatives. She described the Calyrex biosimilar insulin initiative as a state-backed program that will make insulin glargine pens available to consumers starting Jan. 1, 2026 at a maximum patient price of $55 for a 5-pack and said pharmacies will be able to purchase the product for $45. "This initiative really underscores California's commitment to improving medication affordability," Lansberg said.
Lansberg said HCAI has increased tribal engagement in advance of California's Rural Health Transformation Program application under federal HR1, describing the national NOFO as a five-year, $50 billion program to strengthen rural health delivery. Her presentation described three priority…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
